Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail.
November 1, 2023

Consolidated Financial Results
for the First Six Months of the Fiscal Year Ending March 31, 2024
(Under Japanese GAAP)
Listed Company: Zeria Pharmaceutical Co., Ltd.
(Stock Exchange: Tokyo Stock Exchange)
Code Number: 4559
(URL: https://www.zeria.co.jp/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division
TEL (03) 3661-1039
Scheduled date to submit the Quarterly Securities Report: November 6, 2023
Scheduled date to commence dividend payments:
December 1, 2023
Preparation of supplementary documents to the quarterly financial results:
Yes
Holding of quarterly financial results presentation:
Yes (for analysts, institutional investors and the press)(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2023 through September 30, 2023)(1) Consolidated Financial Results (cumulative)(Percentage figures indicate changes from the same period of the previous year.)
Profit attributable toOperating profit
Ordinary profit
owners of parent

Net sales
Six months ended

Million yen%

Million yen%

Million yen%

Million yen%

September 30, 2023

36,678

8.8

5,327

(9.6)

5,495

6.1

5,396

35.0

September 30, 2022

33,712

17.9

5,894

120.6

5,182

66.3

3,998

89.0

Note: Comprehensive income: For the six months ended September 30, 2023: 11,254 million yen [39.5%]
For the six months ended September 30, 2022: 8,069 million yen [267.7%]

Basic earnings
per share

Diluted earnings
per share

Six months ended

Yen

Yen

September 30, 2023

122.43–September 30, 2022

90.41

–

(2) Consolidated Financial Position
Total assets
As of

Net assets

Equity ratio

Net assets per share

Million yen

Million yen%

Yen

September 30, 2023

148,158

75,96251.1

1,717.40

March 31, 2023

135,034

65,68048.5

1,484.79

Reference: Equity: As of September 30, 2023: 75,703 million yen

As of March 31, 2023: 65,449 million yen

2. Dividends
Annual dividends
First quarter

Second quarter

Third quarter

Yen

Yen

Yen

Yen

Yen

Year ended
March 31, 2023

–

18.00

–

22.00

40.00

Year ending
March 31, 2024

–

22.00
–

22.00

44.00

Year ending
March 31, 2024 (Forecast)
Note: Revision of the forecast of dividends most recently announced: None

Year-endTotal

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024 (April 1, 2023 through March 31, 2024)(Percentage figures indicate changes from the same period of the previous year.)
Basic
Profit attributable toOperating profit
Ordinary profit
earnings perowners of parent
share

Net sales

Full year

Million yen%

Million yen%

Million yen%

Million yen%

Yen

73,000

6.8

9,100

0.9

9,000

18.7

7,000

13.0

158.80Note: Revision of the financial forecast most recently announced: None

* Notes(1) Changes in significant subsidiaries during the six months ended September 30, 2023 (changes in specified subsidiaries
resulting in changes in scope of consolidation): None
Inclusion: – (Company name: –)Exclusion: – (Company name: –)(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes
Note: For details, please refer to “2. Quarterly Consolidated Financial Statements and Significant Notes Thereto, (4) Notes to quarterly
consolidated financial statements” on page 10 of the Attached Material.

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after
error corrections
1) Changes in accounting policies due to revisions to accounting standards and other regulations: None
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: None
4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common shares)
1) Number of shares issued as of the end of the term (including treasury shares):
As of September 30, 2023: 53,119,190 shares
As of March 31, 2023: 53,119,190 shares
2) Number of shares of treasury shares as of the end of the term:
As of September 30, 2023: 9,039,119 shares
As of March 31, 2023: 9,038,982 shares
3) Average number of shares during the period (cumulative from the beginning of the fiscal year):
For the six months ended September 30, 2023: 44,080,153 shares
For the six months ended September 30, 2022: 44,229,546 shares* Quarterly Results Reports Are Exempt from Quarterly Review Conducted by Certified Public Accountants or
An Audit Corporation* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters
The description about the future including the projection in this document is based on information available to the Company
at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do notconstitute assurances regarding actual results by the Company. The actual results for future terms may differ from theinformation in this document due to various factors. For the assumptions made in financial forecasts and cautions concerning
the use thereof, please refer to “1. Qualitative Information on Quarterly Financial Results, (3) Explanation of consolidated
financial forecasts and other forward-looking statements” on page 4 of the Attached Material.

○Table of contents of attachments
1. Qualitative Information on Quarterly Financial Results ......................................................................................2(1) Explanation of operating results .................................................................................................................................. 2(2) Explanation of financial position ................................................................................................................................. 3(3) Explanation of consolidated financial forecasts and other forward-looking statements .......................................... 4
2. Quarterly Consolidated Financial Statements and Significant Notes Thereto .....................................................5(1) Quarterly consolidated balance sheet .......................................................................................................................... 5(2) Quarterly consolidated statement of income and quarterly consolidated statement of comprehensive income .... 7
Quarterly consolidated statement of income ..................................................................................................7
Quarterly consolidated statement of comprehensive income.........................................................................8(3) Quarterly consolidated statement of cash flows ......................................................................................................... 9(4) Notes to quarterly consolidated financial statements ...............................................................................................10(Notes on premise of a going concern) ........................................................................................................10(Notes on significant changes in the amount of shareholders’ equity) ........................................................10(Adoption of special accounting methods for preparation of quarterly consolidated financial statements) 10(Segment information, etc.) ......................................................................................................................... 11
3. Supplemental Information ..................................................................................................................................12(1) Sales results .................................................................................................................................................................12(2) Sales of major products and merchandise Consolidated ..........................................................................................13(3) Status of pipeline of new drugs ..................................................................................................................................14

1

1. Qualitative Information on Quarterly Financial Results(1) Explanation of operating results
Net sales for the first six months of the fiscal year ending March 31, 2024 were 36,678 million yen (up 8.8%
from the same period of the previous fiscal year). At the same time, operating profit was 5,327 million yen(down 9.6% from the same period of the previous fiscal year) due to the increase in expenditures resulting
from a partial revision of the pharmaceutical price regulation scheme in the UK in addition to increases
mainly in promotion expenses and depreciation. Ordinary profit was 5,495 million yen (up 6.1% from thesame period of the previous fiscal year) as a result of recording a small amount of foreign exchange gains forthe period under review despite recording a large amount of foreign exchange losses from the sudden
appreciation of the Swiss franc during the previous period. Profit attributable to owners of parent was 5,396
million yen (up 35.0% from the same period of the previous fiscal year) as a result of recording reversal ofprovision for loss on cancellation of contracts as extraordinary income.
Following are the results by business segment.
(i) Ethical Pharmaceuticals Business
As for our mainstay product, Asacol, a therapeutic agent for ulcerative colitis, sales in the domestic
market faced challenging circumstances, owing in part to the impact of the NHI drug price revision
implemented in April of 2023. Despite this, sales were steady overall as a result of strong performance inregions such as the UK and Germany due to growth in sales of Asacol 1600 mg in overseas markets. Salesof DIFICLIR, a therapeutic agent for Clostridium difficile infections, achieved a significant sales growth
as a result of continuous aggressive investment of sales resources in overseas markets, which lead to asignificant increase in sales in France, the UK, and Spain. In April 2023, we were transferred approval
from Astellas Pharma Inc. for the manufacturing and marketing of the drug in Japan and worked topromote the product (domestic sales name: Dafclir). However, sales of Entocort (domestic sales name:Zentacort), an inflammatory bowel disease (IBD) therapeutic agent, struggled after the launch of genericdrugs in certain countries outside Japan. With regard to Ferinject, we are working to build the market,
particularly in the obstetrics and gynecology and gastroenterology fields.
As a result, net sales in the business amounted to 23,900 million yen (up 11.1% from the same period of
the previous fiscal year).
(ii) Consumer Healthcare Business
As for the Hepalyse range, our mainstay product, due to the relaxing of behavioral restrictions related to
the COVID-19 pandemic and recovery in the flow of people, sales of both the pharmaceutical Hepalyse
range and the Hepalyse W range for convenience stores increased. Sales of the Chondroitin range also
remained strong, due in part to aggressive advertising and promotional investments. In addition, sales
increased for both the European herbal preparation range, including Prefemin, a treatment forpremenstrual syndrome (PMS), which transferred to a Type-2 OTC drug in April 2023, and the Masdent
range of medicated toothpaste for preventing periodontal disease and bad breath.
As a result, net sales in the business amounted to 12,700 million yen (up 4.7% from the same period of theprevious fiscal year).
(iii) Other
Net sales in this segment amounted to 77 million yen (up 1.9% from the same period of the previous fiscal
year), mainly due to insurance agency business and real estate lease revenue.

2(2) Explanation of financial position(i) Assets, liabilities, and net assets
Total assets at the end of the second quarter of the fiscal year ending March 31, 2024 were 148,158
million yen, an increase of 13,124 million yen from the end of the previous fiscal year. Current assets
increased 7,752 million yen to 55,956 million yen from the end of the previous fiscal year, and noncurrent assets increased 5,371 million yen to 92,202 million yen from the end of the previous fiscal year.
Major changes in current assets included an increase of 2,248 million yen in cash and deposits, anincrease of 4,146 million yen in notes and accounts receivable - trade, and an increase of 1,520 million
yen in inventories such as merchandise and finished goods. The changes in non-current assets were an
increase of 990 million yen in property, plant and equipment, an increase of 2,725 million yen in
intangible assets, and an increase of 1,655 million yen in investments and other assets.
Total liabilities at the end of the quarter under review were 72,196 million yen, an increase of 2,842
million yen from the end of the previous fiscal year. Current liabilities increased 5,863 million yen to
53,021 million yen from the end of the previous fiscal year, and non-current liabilities decreased 3,020
million yen to 19,174 million yen from the end of the previous fiscal year. Main changes in current
liabilities were an increase of 1,067 million yen in accounts payable - trade, an increase of 3,648 million
yen in short-term borrowings and an increase of 982 million yen in income taxes payable. Main changes
in non-current liabilities were a decrease of 2,523 million yen in long-term borrowings and a decrease of
897 million yen in provision for loss on cancellation of contracts.
Net assets at the end of the quarter under review were 75,962 million yen, an increase of 10,281 million
yen from the end of the previous fiscal year. This was mainly due to profit attributable to owners of parentof 5,396 million yen, payment of 969 million yen as dividends declared at the end of the previous period,
and an increase of 4,824 million yen in foreign currency translation adjustment.
As a result, equity ratio at the end of the quarter under review increased by 2.6% from the end of theprevious fiscal year to 51.1%.
(ii) Status of cash flows
Cash and cash equivalents (below, “cash”) at the end of the quarter under review increased 2,248 million
yen from the beginning of the period to 18,343 million yen. This was mainly due to net cash provided byoperating activities of 4,964 million yen, despite net cash used in investing activities of 2,186 million yen
and net cash used in financing activities of 2,285 million yen.
The status of each cash flow and its factors for the first six months of the current fiscal year are as follows.
[Net cash provided by (used in) operating activities]
Net cash provided by operating activities amounted to 4,964 million yen in the first six months of thecurrent fiscal year (down 367 million yen from the same period of the previous fiscal year). This was due
to factors including profit before income taxes of 6,412 million yen, depreciation of 3,031 million yen, adecrease in provision for loss on cancellation of contracts of 923 million yen, an increase in tradereceivables of 2,804 million yen, an increase in inventories of 824 million yen, and an increase in trade
payables of 1,034 million yen.
[Net cash provided by (used in) investing activities]
Net cash used in financing activities totaled 2,186 million yen in the first six months of the current fiscal
year (down 1,223 million yen from the same period of the previous fiscal year). This was mainly due to
expenditures of 1,395 million yen for the purchase of property, plant and equipment and 888 million yen
for the purchase of intangible assets.

3

[Net cash provided by (used in) financing activities]
Net cash used in financing activities totaled 2,285 million yen in the first six months of the current fiscal
year (down 166 million yen from the same period of the previous fiscal year). This was mainly due to anincrease of 1,168 million yen in short-term borrowings, proceeds from long-term borrowings of 500
million yen, repayments of long-term borrowings of 2,824 million yen, and dividends paid of 966 million
yen.
(3) Explanation of consolidated financial forecasts and other forward-looking statements
The full-year consolidated financial forecasts for the fiscal year ending March 31, 2024 are expected tomainly be in line with expectations, primarily in the overseas Ethical Pharmaceuticals Business, and we areleaving the full-year figures announced on May 11, 2023 unchanged due to uncertainties about the impact ofsoaring raw material and energy prices and exchange rate trends. If it becomes necessary to revise thefinancial forecast, we will disclose the revised forecast promptly.

4

2. Quarterly Consolidated Financial Statements and Significant Notes Thereto(1) Quarterly consolidated balance sheet(Thousands of yen)
As of March 31, 2023
AssetsCurrent assets
Cash and deposits
Notes and accounts receivable - trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings, net
Land
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Sales right
Other
Total intangible assets
Investments and other assets
Investment securities
Retirement benefit asset
Other
Allowance for doubtful accounts
Total investments and other assets
Total non-current assets
Total assets
Liabilities
Current liabilities
Accounts payable - trade
Short-term borrowings
Income taxes payable
Provision for bonuses
Other
Total current liabilities
Non-current liabilities
Long-term borrowings
Provision for loss on cancellation of contracts
Retirement benefit liability
Asset retirement obligations
Other
Total non-current liabilities
Total liabilities

5

As of September 30, 2023

16,219,078
17,512,925
6,843,723
1,433,308
4,487,158
1,800,930(93,366)
48,203,757

18,468,022
21,659,778
8,018,926
1,373,181
4,892,884
1,635,979(92,496)
55,956,275

6,772,573
12,359,997
5,458,805
24,591,375

6,662,008
12,474,232
6,445,597
25,581,838

5,299,798
28,157,670
8,473,201
41,930,669

5,133,326
30,191,579
9,331,334
44,656,240

6,849,304
12,927,173
578,716(46,460)
20,308,733
86,830,779
135,034,536

8,535,278
12,918,910
551,177(40,874)
21,964,492
92,202,571
148,158,847

1,996,122
34,890,470
749,106
1,554,662
7,967,956
47,158,318

3,063,342
38,539,273
1,731,739
1,043,674
8,643,360
53,021,390

14,541,480
897,300
234,465
56,031
6,466,230
22,195,507
69,353,826

12,018,050–
216,826
56,135
6,883,966
19,174,97872,196,369

(Thousands of yen)
As of March 31, 2023
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders’ equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets

6

As of September 30, 2023

6,593,398
11,685,121
53,462,589(18,264,989)
53,476,120

6,593,398
11,685,121
57,889,601(18,265,312)
57,902,808(314,469)
8,015,623
4,272,642
11,973,796
230,793
65,680,710
135,034,536

949,991
12,840,432
4,009,909
17,800,333
259,335
75,962,478
148,158,847

(2) Quarterly consolidated statement of income and quarterly consolidated statement of comprehensive
incomeQuarterly consolidated statement of income(Thousands of yen)Six months ended
September 30, 2022
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating profit
Non-operating income
Interest income
Dividend income
Foreign exchange gains
Recoveries of written off receivables
Other
Total non-operating income
Non-operating expenses
Interest expenses
Foreign exchange losses
Other
Total non-operating expenses
Ordinary profit
Extraordinary income
Gain on sale of non-current assets
Gain on sale of investment securities
Reversal of provision for loss on cancellation ofcontracts
Total extraordinary income
Extraordinary losses
Loss on retirement of non-current assets
Provision for loss on cancellation of contracts
Total extraordinary losses
Profit before income taxes
Income taxes
ProfitProfit attributable to non-controlling interests
Profit attributable to owners of parent

7

Six months ended
September 30, 2023

33,712,480
9,376,722
24,335,758
18,441,079
5,894,678

36,678,404
9,631,957
27,046,446
21,719,007
5,327,439

26,461
158,136––
45,555230,153

46,176
192,672
1,017
89,761
77,461
407,090

181,259
748,121
13,205942,586
5,182,245

226,110–
12,481
238,591
5,495,938

260
19,940–0–923,331

20,200923,332

3,350
228,300
231,651
4,970,794
964,014
4,006,779
8,199
3,998,580

6,336
–
6,336
6,412,933
1,005,062
5,407,870
11,093
5,396,776

Quarterly consolidated statement of comprehensive income(Thousands of yen)Six months ended
September 30, 2022
ProfitOther comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Remeasurements of defined benefit plans, net of tax
Total other comprehensive income
Comprehensive income
Comprehensive income attributable toComprehensive income attributable to owners of parent
Comprehensive income attributable to non-controllinginterests

8

Six months ended
September 30, 2023

4,006,779

5,407,870(264,896)
4,476,703(148,940)
4,062,866
8,069,646

1,264,461
4,844,478(262,732)
5,846,207
11,254,078

8,023,106

11,223,314

46,53930,764

(3) Quarterly consolidated statement of cash flows(Thousands of yen)Six months ended
September 30, 2022
Cash flows from operating activities
Profit before income taxes
Depreciation
Amortization of goodwill
Increase (decrease) in provision for bonuses
Increase (decrease) in provision for loss on cancellationof contracts
Increase (decrease) in retirement benefit liability
Interest and dividend income
Interest expenses
Decrease (increase) in trade receivables
Decrease (increase) in inventories
Increase (decrease) in trade payables
Decrease (increase) in other current assets
Increase (decrease) in other current liabilities
Decrease (increase) in retirement benefit asset
Other, net
SubtotalInterest and dividends received
Interest paid
Income taxes paid
Net cash provided by (used in) operating activities
Cash flows from investing activities
Purchase of property, plant and equipment
Purchase of intangible assets
Purchase of investment securities
Proceeds from sale of investment securities
Other, net
Net cash provided by (used in) investing activities
Cash flows from financing activities
Net increase (decrease) in short-term borrowings
Proceeds from long-term borrowings
Repayments of long-term borrowings
Repayments of lease liabilities
Purchase of treasury shares
Dividends paid
Dividends paid to non-controlling interests
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash
equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period

9

Six months ended
September 30, 2023

4,970,794
2,466,358
354,879(514,895)

6,412,933
3,031,173
363,836(562,105)

228,300(923,331)

109,324(184,597)
181,259(1,289,682)(409,623)
193,809(164,194)
215,451(354,809)(117,947)
5,684,428
184,616(180,360)(356,493)
5,332,190(17,638)(238,849)
226,110(2,804,465)(824,917)
1,034,301(74,785)
549,034(493,330)(286,874)
5,391,092
238,593(216,497)(448,416)
4,964,771(908,651)(156,032)(132,488)
215,908
17,787(963,476)(1,395,136)(888,433)(2,313)
1
99,315(2,186,567)

1,873,266
500,000(3,028,710)(123,158)(538,398)(798,347)(3,929)(2,119,276)

1,168,875
500,000(2,824,420)(160,870)(323)(966,355)(2,308)(2,285,403)

1,340,254

1,756,142

3,589,691
11,579,282
15,168,974

2,248,943
16,094,078
18,343,022

(4) Notes to quarterly consolidated financial statements(Notes on premise of a going concern)
Not applicable.
(Notes on significant changes in the amount of shareholders’ equity)
Not applicable.
(Adoption of special accounting methods for preparation of quarterly consolidated financial statements)
Calculation of tax expenses
Tax expenses were calculated by reasonably estimating the effective tax rate after applying tax effectaccounting to the profit before income taxes for the fiscal year that includes the second quarter of the current
fiscal year and multiplying profit before income taxes by such estimated effective tax rate.

10

(Segment information, etc.)[Segment information]
I First six months of the previous fiscal year (from April 1, 2022 to September 30, 2022)
1. Information on net sales and profit or loss by reportable segment(Thousands of yen)

Adjustment(Note 2)

Amountrecorded inquarterly
consolidated
statement ofincome(Note 3)33,712,480–

33,712,480

219,681

222,434(222,434)–

33,639,517

295,398

33,934,915(222,434)

33,712,480

8,322,853

116,456

8,439,309(2,544,631)

5,894,678

Reportable segment
Other(Note 1)

EthicalPharmaceuticals
Business

Consumer
Healthcare
Business

Total

21,505,406

12,131,357

33,636,763

75,716

2,694

58

2,753

21,508,101

12,131,416

5,867,879

2,454,974

Total

Net sales
Sales to externalcustomers
Intersegment
sales and transfers
Total
Segment profit(Notes) 1. “Other” is a business segment not included in the reportable segments and includes the insurance agency businessand real estate business.
2. Adjustment of segment profit of (2,544,631) thousand yen is mainly corporate expenses, such as general andadministrative expenses that are not allocated to reportable segments.
3. Segment profit is adjusted with operating profit in the quarterly consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment
Not applicable.
II First six months of the current fiscal year (from April 1, 2023 to September 30, 2023)
1. Information on net sales and profit or loss by reportable segment(Thousands of yen)

Adjustment(Note 2)

Amountrecorded inquarterly
consolidated
statement ofincome(Note 3)36,678,404–

36,678,404

320,078

323,099(323,099)–

36,604,300

397,202

37,001,503(323,099)

36,678,404

7,784,109

124,092

7,908,202(2,580,762)

5,327,439

Reportable segment

Net sales
Sales to externalcustomers
Intersegment
sales and transfers
Total
Segment profit

Other(Note 1)

EthicalPharmaceuticals
Business

Consumer
Healthcare
Business

Total

23,900,997

12,700,282

36,601,280

77,124

2,958

62

3,020

23,903,955

12,700,344

5,257,968

2,526,140

Total(Notes) 1. “Other” is a business segment not included in the reportable segments and includes the insurance agency businessand real estate business.
2. Adjustment of segment profit of (2,580,762) thousand yen is mainly corporate expenses, such as general andadministrative expenses that are not allocated to reportable segments.
3. Segment profit is adjusted with operating profit in the quarterly consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment
Not applicable.

113. Supplemental Information(1) Sales results
The table below shows sales results by business segment in the first six months of the current fiscal year.
(Thousands of yen)First six months ofthe current fiscal year
(from April 1, 2023
to September 30, 2023)

Name of segment

Increase/(decrease)over the same period of
the previous fiscal year (%)

Ethical Pharmaceuticals Business

23,900,997

11.1

Consumer Healthcare Business

12,700,282

4.7

36,601,280

8.8

77,124

1.9

36,678,404

8.8

Total reportable segment
Other
Total
(Note)

Inter-segment transactions are offset and eliminated.

12

(2) Sales of major products and merchandise Consolidated(Thousands of yen)First six months ofthe previous fiscal year
(from April 1, 2022
to September 30, 2022)

First six months ofthe current fiscal year
(from April 1, 2023
to September 30, 2023)

Percentage change(%)

21,505,406

23,900,997

11.1

Asacol9,881,146

10,097,551

2.2

DIFICLIR

3,895,442

6,545,802

68.0

Entocort

2,935,555

2,447,326(16.6)

Acofide1,541,840

1,522,454

(1.3)

Other

3,251,421

3,287,862

1.1

12,131,357

12,700,282

4.7

Hepalyse range

4,698,724

5,190,313

10.5

Chondroitin range

2,634,015

2,862,851

8.7

WithOne range

620,943

612,894(1.3)

4,177,673

4,034,223(3.4)

75,716

77,124

1.9

33,712,480

36,678,404

8.8

1. Ethical Pharmaceuticals Business

2. Consumer Healthcare Business

Other
3. Other Business
Total

13

(3) Status of pipeline of new drugs
I.

Domestic

As of November 1, 2023

Stage

Development Code/
Generic Name

Development

Indications

Classification

OriginNDA filed

ZG-801/Patiromer
Sorbitex Calcium

Zeria

Hyperkalemia

Potassium binder

In-licensed

Phase IIIZ-338/Acotiamide

Zeria

Pediatric functional
dyspepsia

Upper gastrointestinal
motility modulator

Original

Phase II

ZG-802/Acotiamide

Zeria

Underactive bladder

Lower urinary tract
function modulator

Original

Phase II*
(Investigator-InitiatedTrial)

Z-338/Acotiamide

KyushuUniversity

Esophagogastricjunction outflow
obstruction

Upper gastrointestinal
motility modulator

Original*: Supported by a grant from Japan Agency for Medical Research and Development (AMED)II. Overseas
Stage

Development Code/
Generic Name

Development

Indications

Classification

OriginPhase III(Europe)

Z-338/Acotiamide

Zeria

Functional
dyspepsia

Upper gastrointestinal
motility modulator

Original

NDA approved(Honduras,
Dominican Republic,
Ecuador, Chile,
El Salvador, Peru)

Z-338/Acotiamide

Faes Farma

Functional
dyspepsia

Upper gastrointestinal
motility modulator

Original(Out-licensed)

NDA approved(Thailand)

Z-338/Acotiamide

Meiji Seika
PharmaFunctional
dyspepsia

Upper gastrointestinal
motility modulator

Original(Out-licensed)

NDA filed(Vietnam)Z-338/Acotiamide

Pharmaceutical
Joint Stock
Company ofFebruary 3rd

Functional
dyspepsia

Upper gastrointestinal
motility modulator

Original

NDA filed(Colombia,
Costa Rica,
Guatemala, Panama,
Nicaragua)Z-338/Acotiamide

Faes Farma

Functional
dyspepsia

Upper gastrointestinal
motility modulator

Original(Out-licensed)

Launched in Overseas
Launch Date

Development Code/
Generic Name

Development

Indications

Classification

OriginOctober 2023
(Mexico)Z-338/Acotiamide

Faes Farma

Functional
dyspepsia

Upper gastrointestinal
motility modulator

Original(Out-licensed)

14